Walden Biosciences
Aref Shahini has worked at Walden Biosciences as a Pharmacology Scientist since 2022. Prior to that, they were a Postdoctoral Researcher at Harvard Medical School from 2020-2022. Aref also worked as a Research Assistant at the University at Buffalo Chemical and Biological Eng. PhD Program from 2013-2020 and at Oklahoma State University from 2012-2013.
Aref Shahini obtained their Bachelor of Science in Chemical Engineering from Sharif University of Technology between 2008 and 2012. Aref then continued their education at the University at Buffalo, earning their PhD in Chemical and Biological Engineering in 2019.
This person is not in any offices
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.